UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1 Elucidating the role of inflammatory mediators in cisplatin resistant NSCLC

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S1-S1

2013

Volltextzugriff (PDF)

1 Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S1-S1

2014

Volltextzugriff (PDF)

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S4-S4

2014

Volltextzugriff (PDF)

10 Targeting the IGF-1R signalling pathway in non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S4-S4

2011

Volltextzugriff (PDF)

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

Annals of oncology, 2022-09, Vol.33, p.S1017

2022

Volltextzugriff (PDF)

1153P A first in class DNA repair inhibitor for the treatment of NSCLC

Annals of oncology, 2022-09, Vol.33, p.S1076-S1077

2022

Volltextzugriff (PDF)

12 VEGF autocrine survival signalling is mediated via neuropilin 1 receptor in NSCLC cells

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S5-S5

2014

Volltextzugriff (PDF)

1243PDACOMITINIB (D) VERSUS ERLOTINIB (E) IN 2ND/3RD LINE NSCLC: OUTCOME FOR ASIAN PATIENTS FROM THE ARCHER 1009 GLOBAL PHASE 3 TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv435-iv435

2014

Volltextzugriff (PDF)

1251PUPDATED ANALYSIS OF RESPONSE AND PATIENT-REPORTED OUTCOMES (PRO) IN TWO LARGE OPEN-LABEL, PHASE III STUDIES (LUX-LUNG 3 [LL3] AND LUX-LUNG 6 [LL6]) OF AFATINIB (A) VERSUS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH ADVANCED NSCLC HARBORING EGFR MUTATIONS (MUT)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv439-iv439

2014

Volltextzugriff (PDF)

1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227

Annals of oncology, 2020-09, Vol.31, p.S824-S824

2020

Volltextzugriff (PDF)

1302P Immune signatures of second-line PD-1 immune checkpoint blockade

Annals of oncology, 2021-09, Vol.32, p.S1007-S1007

2021

Volltextzugriff (PDF)

1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials

Annals of oncology, 2024-09, Vol.35, p.S830-S831

2024

Volltextzugriff (PDF)

134P Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)

Annals of oncology, 2024-09, Vol.35, p.S269-S269

2024

Volltextzugriff (PDF)

1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation

Annals of oncology, 2024-09, Vol.35, p.S872-S873

2024

Volltextzugriff (PDF)

148P - Targeting NFKB in Cisplatin Resistant NSCLC

Annals of oncology, 2012-09, Vol.23, p.ix68-ix68

2012

Volltextzugriff (PDF)

149P - Microrna Profiling and CDDP-GPG DNA Adduct Formation Analysis in a Panel of Cisplatin Resistant Non-Small Cell Lung Cancer Cell Lines

Annals of oncology, 2012-09, Vol.23, p.ix68-ix68

2012

Volltextzugriff (PDF)

150P - IL-23 is Epigenetically Regulated and Induced by Chemotherapy in NSCLC

Annals of oncology, 2012-09, Vol.23, p.ix68-ix69

2012

Volltextzugriff (PDF)

1531P - Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma

Annals of oncology, 2012-09, Vol.23, p.ix495-ix495

2012

Volltextzugriff (PDF)

1532P - High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma

Annals of oncology, 2012-09, Vol.23, p.ix495-ix495

2012

Volltextzugriff (PDF)

154P - Co-Targeting The PI3K-MTOR & MEK Pathways in NSCLC

Annals of oncology, 2012-09, Vol.23, p.ix69-ix70

2012

Volltextzugriff (PDF)

162P - Circulating tumour cells in head and neck and non-small cell lung cancer

Annals of oncology, 2019-10, Vol.30, p.v51-v51

O’Byrne, K.J.

2019

Volltextzugriff (PDF)

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

Annals of oncology, 2021-12, Vol.32, p.S1380

2021

Volltextzugriff (PDF)

1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

Annals of oncology, 2024-09, Vol.35, p.S1061-S1062

2024

Volltextzugriff (PDF)

1801P Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide

Annals of oncology, 2024-09, Vol.35, p.S1069-S1070

2024

Volltextzugriff (PDF)

185P - Activation of Akt by Hypoxia Predicts Poor Outcome in Malignant Pleural Mesothelioma (MPM)

Annals of oncology, 2012-09, Vol.23, p.ix78-ix78

2012

Volltextzugriff (PDF)

1 – 25 von 179

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(174)

Publikationsform

Artikel
(178)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(82)
Pulmonary/respiratory
(76)
Life Sciences & Biomedicine
(32)
Science & Technology
(32)
Humans
(31)
Oncology
(30)
Biological And Medical Sciences
(20)
Female
(20)
Medical Sciences
(18)
Male
(17)
Aged
(16)
Middle Aged
(15)
Adult
(12)
Chemotherapy
(12)
Prognosis
(11)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Lung Neoplasms - Drug Therapy
(9)
Lung Neoplasms - Pathology
(9)
Pneumology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

1 Elucidating the role of inflammatory mediators in cisplatin resistant NSCLC

1 Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer

10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980

10 Targeting the IGF-1R signalling pathway in non-small cell lung cancer (NSCLC)

1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer

1153P A first in class DNA repair inhibitor for the treatment of NSCLC

12 VEGF autocrine survival signalling is mediated via neuropilin 1 receptor in NSCLC cells

1243PDACOMITINIB (D) VERSUS ERLOTINIB (E) IN 2ND/3RD LINE NSCLC: OUTCOME FOR ASIAN PATIENTS FROM THE ARCHER 1009 GLOBAL PHASE 3 TRIAL

1251PUPDATED ANALYSIS OF RESPONSE AND PATIENT-REPORTED OUTCOMES (PRO) IN TWO LARGE OPEN-LABEL, PHASE III STUDIES (LUX-LUNG 3 [LL3] AND LUX-LUNG 6 [LL6]) OF AFATINIB (A) VERSUS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH ADVANCED NSCLC HARBORING EGFR MUTATIONS (MUT)

1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227

1302P Immune signatures of second-line PD-1 immune checkpoint blockade

1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials

134P Unraveling functionally distinct metabolic programs to predict immunotherapy response in non-small cell lung cancer (NSCLC)

1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation

148P - Targeting NFKB in Cisplatin Resistant NSCLC

149P - Microrna Profiling and CDDP-GPG DNA Adduct Formation Analysis in a Panel of Cisplatin Resistant Non-Small Cell Lung Cancer Cell Lines

150P - IL-23 is Epigenetically Regulated and Induced by Chemotherapy in NSCLC

1531P - Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma

1532P - High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma

154P - Co-Targeting The PI3K-MTOR & MEK Pathways in NSCLC

162P - Circulating tumour cells in head and neck and non-small cell lung cancer

16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer

1786O BMS-986012 (anti-fucosyl-monosialoganglioside-1 [fuc-GM1]) with carboplatin + etoposide + nivolumab (CE/NIVO) as first-line (1L) therapy in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis (IA) of a randomized phase II study

1801P Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide

185P - Activation of Akt by Hypoxia Predicts Poor Outcome in Malignant Pleural Mesothelioma (MPM)

Suchergebnisse filtern